MS
76
2
AKAM
50
7
PPL
59
5
CMCSA
52
4
PWR
72
2
LRCX
45
6
AVY
50
2
FLS
75
2
FRT
45
6
AEP
53
2
STT
64
4
WAT
53
6
FTI
76
3
EXC
56
2
USB
61
11
EMN
56
7
ADI
47
2
INTU
54
3
MAR
65
2
EMC
53
5
MS
76
2
AKAM
50
7
PPL
59
5
CMCSA
52
4
PWR
72
2
LRCX
45
6
AVY
50
2
FLS
75
2
FRT
45
6
AEP
53
2
STT
64
4
WAT
53
6
FTI
76
3
EXC
56
2
USB
61
11
EMN
56
7
ADI
47
2
INTU
54
3
MAR
65
2
EMC
53
5
Financhill
Back

Karyopharm Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
28

KPTI
Karyopharm Therapeutics

Last Price:
0.85
Seasonality Move:
-2.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Karyopharm Therapeutics Price Quote

$0.85
+0.07 (+9.31%)
(Updated: November 22, 2024 at 5:55 PM ET)

Karyopharm Therapeutics Key Stats

Sell
28
Karyopharm Therapeutics (KPTI) is a Sell
Day range:
$0.76 - $0.80
52-week range:
$0.62 - $1.95
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.67
P/B ratio:
0%
Volume:
278.5K
Avg. volume:
781K
1-year change:
5.34%
Market cap:
$97.4M
Revenue:
$146M
EPS:
$-1.14

How Much Does Karyopharm Therapeutics Make?

Is Karyopharm Therapeutics Growing As A Company?

Karyopharm Therapeutics Stock Price Performance

What Is Karyopharm Therapeutics 52-Week High & Low?

Karyopharm Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Karyopharm Therapeutics?

Is Karyopharm Therapeutics Cash Flow Positive?

  • What Is KPTI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$120.3M
  • What Is Karyopharm Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $0
  • What Is Karyopharm Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $107.5M

Karyopharm Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KPTI return on invested capital is -221.89%
  • What Is Karyopharm Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -39.11%
  • What Is KPTI Return On Equity?
    ROE is a measure of profitability and is 0%

Karyopharm Therapeutics Earnings Date & Stock Price

Karyopharm Therapeutics Competitors

Karyopharm Therapeutics Dividend Yield

Karyopharm Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.64%
Revenue: 7.7% 2.27%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 4.50
Upside from Last Price: 478.7%

Major Shareholders

  • How many KPTI shares are owned by institutional investors?
    97.3M KPTI shares are owned by institutional investors
  • How many KPTI shares are owned by insiders?
    5.2M KPTI shares are owned by insiders